Vermillion, Inc. (NASDAQ:VRML) saw a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 1,510,761 shares, an increase of 85.7% from the February 28th total of 813,691 shares. Approximately 3.6% of the shares of the company are sold short. Based on an average daily trading volume, of 368,013 shares, the days-to-cover ratio is presently 4.1 days.
In related news, Director David Schreiber sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $1.00, for a total value of $30,000.00. Following the transaction, the director now owns 137,405 shares of the company’s stock, valued at $137,405. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 4.25% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Vermillion by 16.9% during the third quarter. Vanguard Group Inc. now owns 1,452,612 shares of the company’s stock valued at $1,031,000 after buying an additional 209,600 shares during the last quarter. Vanguard Group Inc raised its position in shares of Vermillion by 16.9% during the third quarter. Vanguard Group Inc now owns 1,452,612 shares of the company’s stock valued at $1,031,000 after buying an additional 209,600 shares during the last quarter. Essex Investment Management Co. LLC bought a new stake in shares of Vermillion during the fourth quarter valued at approximately $103,000. Greenwich Wealth Management LLC raised its position in shares of Vermillion by 11.3% during the fourth quarter. Greenwich Wealth Management LLC now owns 241,121 shares of the company’s stock valued at $72,000 after buying an additional 24,500 shares during the last quarter. Finally, B. Riley Wealth Management Inc. raised its position in shares of Vermillion by 38.4% during the fourth quarter. B. Riley Wealth Management Inc. now owns 182,245 shares of the company’s stock valued at $55,000 after buying an additional 50,545 shares during the last quarter. Institutional investors own 20.89% of the company’s stock.
Vermillion (NASDAQ:VRML) last released its earnings results on Thursday, March 28th. The company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). Vermillion had a negative net margin of 372.45% and a negative return on equity of 150.85%. The company had revenue of $0.92 million for the quarter.
Vermillion Company Profile
Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.
Further Reading: Hedge Funds Explained
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.